Prescient Therapeutics (ASX: PTX) is a clinical-stage oncology company whose lead asset, PTX-100, is the world’s first-in-class GGTase-1 inhibitor in clinical development — and, as of today, the only drug of its kind targeting relapsed/refractory cutaneous T-Cell Lymphona (CTCL), a very deadly form of cancer. Building a Phase 2 footprint Since our last note, published […]